Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

28.73 +0.55 (+1.97%)
Streaming Delayed Price Updated: 12:57 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Alpha Buying: 3 Stocks With Sky-High Insider Confidence
 
Via Benzinga
Why Scholar Rock Stock Got Socked on Monday
The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects. 
Via The Motley Fool
Topics Earnings
Why Is Scholar Rock Stock Trading Lower On Monday?
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial. 
Via Benzinga
Why Are Regeneron And Scholar Rock Shares Falling On Monday?
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues
Via Stocktwits
Earnings Scheduled For August 6, 2025
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Why Scholar Rock Stock Raced 6% Higher Today
A pundit at an influential U.S. bank is quite bullish on the company's future. 
Via The Motley Fool
This Oracle Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA... 
Via Benzinga
Topics Stocks
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market. 
Via Benzinga
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug. 
Via Investor's Business Daily
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Why Scholar Rock Stock Bounced Higher on Monday
One pundit believes the share price could rise in excess of 50%. 
Via The Motley Fool
How Do Investors Really Feel About Scholar Rock Holding?
 
Via Benzinga
Here's How Much $1000 Invested In Scholar Rock Holding 5 Years Ago Would Be Worth Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Scholar Rock Holding Stock In The Last 5 Years
 
Via Benzinga
Why Scholar Rock Stock Wilted on Wednesday
The market was hoping the company could better contain its losses. 
Via The Motley Fool
Scholar Rock (SRRK) Q2 Loss Widens 63%
Via The Motley Fool
Scholar Rock Holding Corp (NASDAQ:SRRK) Reports Q2 2025 Wider Loss but Market Shows Optimism Ahead of Key FDA Decision
Scholar Rock reports Q2 2025 loss of $0.98 per share but gains investor optimism ahead of FDA decision for apitegromab in SMA. Cash runway extends to 2027. 
Via Chartmill
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year
Via The Motley Fool
Topics Regulatory Compliance
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss
Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said. 
Via Stocktwits
Topics Death
Why Scholar Rock Shares Are Soaring Today
Via The Motley Fool
Topics Stocks
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial. 
Via Benzinga
Which stocks are gapping on Wednesday?
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.